These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38767356)

  • 1. S309-CAR-NK cells bind the Omicron variants
    Ma MT; Jiang Q; Chen C-H; Badeti S; Wang X; Zeng C; Evans D; Bodnar B; Marras SAE; Tyagi S; Bharaj P; Yehia G; Romanienko P; Hu W; Liu S-L; Shi L; Liu D
    J Virol; 2024 Jun; 98(6):e0003824. PubMed ID: 38767356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR-NK Cells Effectively Target SARS-CoV-2-Spike-Expressing Cell Lines
    Ma MT; Badeti S; Chen CH; Kim J; Choudhary A; Honnen B; Reichman C; Calianese D; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
    Front Immunol; 2021; 12():652223. PubMed ID: 34367128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice.
    Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C
    Front Immunol; 2024; 15():1383612. PubMed ID: 38742107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycoprotein Targeted CAR-NK Cells for the Treatment of SARS-CoV-2 Infection.
    Christodoulou I; Rahnama R; Ravich JW; Seo J; Zolov SN; Marple AN; Markovitz DM; Bonifant CL
    Front Immunol; 2021; 12():763460. PubMed ID: 35003077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR-NK Cells Effectively Target the D614 and G614 SARS-CoV-2-infected Cells.
    Ma M; Badeti S; Chen CH; Pinter A; Jiang Q; Shi L; Zhou R; Xu H; Li Q; Gause W; Liu D
    bioRxiv; 2021 Jan; ():. PubMed ID: 33469580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19.
    Lu T; Ma R; Dong W; Teng KY; Kollath DS; Li Z; Yi J; Bustillos C; Ma S; Tian L; Mansour AG; Li Z; Settles EW; Zhang J; Keim PS; Barker BM; Caligiuri MA; Yu J
    Nat Commun; 2022 May; 13(1):2576. PubMed ID: 35546150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Corzo C; Noriega MA; Sánchez-Cordón PJ; Labiod N; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2024; 15():1420304. PubMed ID: 39267752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice.
    Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS
    J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infection by blocking the epidermal growth factor receptor (EGFR) pathway.
    Han Y; Kim S; Park T; Hwang H; Park S; Kim J; Pyun J-c; Lee M
    Microbiol Spectr; 2024 Nov; 12(11):e0158324. PubMed ID: 39291996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
    El-Shennawy L; Hoffmann AD; Dashzeveg NK; McAndrews KM; Mehl PJ; Cornish D; Yu Z; Tokars VL; Nicolaescu V; Tomatsidou A; Mao C; Felicelli CJ; Tsai CF; Ostiguin C; Jia Y; Li L; Furlong K; Wysocki J; Luo X; Ruivo CF; Batlle D; Hope TJ; Shen Y; Chae YK; Zhang H; LeBleu VS; Shi T; Swaminathan S; Luo Y; Missiakas D; Randall GC; Demonbreun AR; Ison MG; Kalluri R; Fang D; Liu H
    Nat Commun; 2022 Jan; 13(1):405. PubMed ID: 35058437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis and analysis of hamster ACE2 binding to different SARS-CoV-2 spike RBDs.
    Niu S; Zhao Z; Liu Z; Rong X; Chai Y; Bai B; Han P; Shang G; Ren J; Wang Y; Zhao X; Liu K; Tian W-x; Wang Q; Gao GF
    J Virol; 2024 Mar; 98(3):e0115723. PubMed ID: 38305152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Bifluorescent-Based Assay for the Identification of Neutralizing Antibodies against SARS-CoV-2 Variants of Concern
    Chiem K; Morales Vasquez D; Silvas JA; Park JG; Piepenbrink MS; Sourimant J; Lin MJ; Greninger AL; Plemper RK; Torrelles JB; Walter MR; de la Torre JC; Kobie JK; Ye C; Martinez-Sobrido L
    J Virol; 2021 Oct; 95(22):e0112621. PubMed ID: 34495697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipsilateral or contralateral boosting of mice with mRNA vaccines confers equivalent immunity and protection against a SARS-CoV-2 Omicron strain.
    Ying B; Liang C-Y; Desai P; Scheaffer SM; Elbashir SM; Edwards DK; Thackray LB; Diamond MS
    J Virol; 2024 Sep; 98(9):e0057424. PubMed ID: 39194250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective Inhibition of the Interaction between SARS-CoV-2 Spike S1 and ACE2 by SPIDAR Peptide Induces Anti-Inflammatory Therapeutic Responses.
    Paidi RK; Jana M; Mishra RK; Dutta D; Pahan K
    J Immunol; 2021 Nov; 207(10):2521-2533. PubMed ID: 34645689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of SARS-CoV-2 IgG Binding Capability to Variants of the SARS-CoV-2 Virus.
    Johnson L; De Gascun CF; Hassan J
    Viral Immunol; 2024 Oct; 37(8):404-410. PubMed ID: 39263777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.
    Schomer NT; Jiang ZK; Lloyd MI; Klingemann H; Boissel L
    Cytotherapy; 2022 Aug; 24(8):827-834. PubMed ID: 35400595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on NK cells.
    Landolina N; Ricci B; Veneziani I; Alicata C; Mariotti FR; Pelosi A; Quatrini L; Mortari EP; Carsetti R; Vacca P; Tumino N; Azzarone B; Moretta L; Maggi E
    Front Immunol; 2024; 15():1368946. PubMed ID: 38881905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.